# EDGAR Filing Document

**Accession Number:** 0001580149
**File Stem:** 0001520138-25-000347
**Filing Date:** 2025-11
**Character Count:** 6175
**Document Hash:** 212dbe05b1e7ebf2da717afe77d5fc16
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001520138-25-000347.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001520138-25-000347

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251110

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOVIE INC.
- **CENTRAL INDEX KEY:** 0001580149
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 462510769
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39015
- **FILM NUMBER:** 251474115

**BUSINESS ADDRESS:**
- **STREET 1:** 680 W NYE LANE
- **STREET 2:** SUITE 201
- **CITY:** CARSON CITY
- **STATE:** NV
- **ZIP:** 89703
- **BUSINESS PHONE:** 775-888-3162

**MAIL ADDRESS:**
- **STREET 1:** 680 W NYE LANE
- **STREET 2:** SUITE 201
- **CITY:** CARSON CITY
- **STATE:** NV
- **ZIP:** 89703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NANOANTIBIOTICS, INC.
- **DATE OF NAME CHANGE:** 20130625

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 10, 2025**

**BioVie Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-39015** | **46-2510769** |
| (State or other jurisdiction of<br> incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **680 W Nye Lane Suite 201**<br> **Carson City, NV** | **89703** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(775) 888-3162**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Class A Common Stock, Par Value $0.0001 Per Share | BIVI | The Nasdaq Stock Market, LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On November 10, 2025, BioVie Inc. (the "Company") held its 2025 annual meeting of stockholders (the "Annual Meeting"). On September 22, 2025, the record date for stockholders entitled to notice of, and to vote at, the Annual Meeting, 7,535,080 shares of the Company's Class A common stock ("Common Stock") were outstanding. The holders of 3,417,857 shares of Common Stock were present at the Annual Meeting, either virtually or represented by proxy, constituting a quorum.

The following matters were considered at the Annual Meeting:

---

| | |
|:---|:---|
| **Proposal 1.** | **Election of Directors** |

---

Stockholders elected all of the Company's nominees for director for one-year terms expiring at the next annual meeting of stockholders and until their respective successors are elected and qualified. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | For | Withhold | Broker Non-Vote |
| (1) AMY CHAPPELL | 1517109 | 36239 | 1864509 |
| (2) CUONG DO | 1513760 | 39588 | 1864509 |
| (3) KAMEEL FARAG | 1513476 | 39872 | 1864509 |
| (4) JAMES LANG | 1513727 | 39621 | 1864509 |
| (5) MICHAEL SHERMAN | 1517074 | 36274 | 1864509 |
| (6) SIGMUND ROGICH | 1512422 | 40926 | 1864509 |

---

---

| | |
|:---|:---|
| **Proposal 2.** | **Ratification of Appointment of Independent Registered Public Accounting Firm** |

---

Stockholders ratified the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2026. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker Non-Vote |
| 3245049 | 141868 | 30940 | 0 |

---

---

| | |
|:---|:---|
| **Proposal 3.** | **Amendment and Restatement of the 2019 Omnibus Equity Incentive Plan** |

---

Stockholders approved an amendment and restatement of the 2019 Omnibus Equity Incentive Plan to increase the number of shares of Common stock Suthorized for issuance to 3,100,000. The voting results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| For | Against | Abstain | Broker Non-Vote |
| 1340062 | 207794 | 5492 | 1864509 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **BioVie** **INC.** | **BioVie** **INC.** | **BioVie** **INC.** |
|  | By: | /s/ Joanne Wendy Kim | /s/ Joanne Wendy Kim |
|  |  | Name: | Joanne Wendy Kim |
|  |  | Title: | Chief Financial Officer |
| Date: November 12, 2025 |  |  |  |

---